Fulcrum Therapeutics(FULC)
Focus: Fulcrum Therapeutics is a public biotech company focused on unlocking gene control mechanisms to develop small molecule therapies, operating in rare diseases, hematology, and infectious diseases from Cambridge, MA.
Profile data last refreshed 3h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Total Funding
$150M
Open Jobs
0
About Fulcrum Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Fulcrum Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Fulcrum Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
2 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$80M
Pipeline & Clinical Trials
FTX-6058/placebo oral capsule
Healthy Adult SubjectsClinical Trials (1)
NCT04586985Safety, Tolerability and Pharmacokinetics of FTX-6058
Phase 1Help build intelligence for Fulcrum Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.